STAT+: Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories
Once top-line results were disclosed, Novo halted two other trials of the drug called HERMES and ATHENA after a data monitoring committee found in September they were unlikely to succeed.
Key points
- The ZEUS results were detailed further on Saturday at the American Heart Association’s scientific sessions and published simultaneously in the New England Journal of Medicine.
- CHICAGO — Out-of-control inflammation is often called the root of all evil in cardiovascular and metabolic disease.
Recent clinical trial results, described in brief in July, showed that while an experimental drug could lower two biomarkers of inflammation, it didn’t limit serious heart events in patients with severe illness.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.